ESR1 mutations are detected in less than 1% of original tumours, however they are reported in 20–40% of tumours after endocrine therapy and have been associated to poor AI & tamoxifen efficacy (O’Neil et al., 2017; Zucchetti et al., 2019; Xu et al., 2020). Here, ESR1 is linked to neoplasm.